Drug Trial Radar · NCT00660907
Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
Last checked: Nov 20, 2026Latest source record: Mar 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,217
Actual
Start
Mar 2008
Primary completion
Dec 2009
Study completion Jan 2013
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Apr 17, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment.
Conditions
- Type 2 Diabetes
Interventions
dapagliflozinDrug
Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks
glipizideDrug
Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks
metformin hydrochlorideDrug
Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adjusted Mean Change in HbA1c LevelsTime frame: Baseline to Week 52
Locations
76 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
Buenos Aires, Argentina
Research Site
Caba, Argentina
Research Site
Capital Federal, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
Corrientes, Argentina
Research Site
La Plata, Argentina
Research Site
Rosario, Argentina
Research Site
Santa Fe, Argentina
Research Site
L'Aigle, France
Research Site
Mûrs-Erigné, France
Research Site
Nantes, France
Research Site
Paris, France
Research Site
Tours, France
Research Site
Vannes, France
Research Site
Bad Lauterberg im Harz, Germany
Research Site
Berlin, Germany
Research Site
Dresden, Germany
Research Site
Essen, Germany
Research Site
Frankfurt, Germany
Research Site
Hamburg, Germany
Research Site
Heilbronn, Germany
Research Site
Ludwigshafen, Germany
Research Site
Mainz, Germany
Research Site
Pirna, Germany
Research Site
Schmiedeberg, Germany
Research Site
Wangen, Germany
Research Site
Perugia, Italy
Research Site
Pisa, Italy
Research Site
Roma, Italy
Research Site
Acapulco, Mexico
Research Site
Guadalajara, Mexico
Research Site
México, Mexico
Research Site
Veracruz, Mexico
Research Site
Deurne, Netherlands
Research Site
Gorinchem, Netherlands
Research Site
Groningen, Netherlands
Research Site
Lichtenvoorde (gld), Netherlands
Research Site
Losser, Netherlands
Research Site
Poortvliet, Netherlands
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.